NMPA approved InnoCare’s Orelabrutinib for the treatment of R/R Marginal Zone Lymphoma

US FDA approved Roche’s Polivy in combination with R-CHP for DLBCL

AstraZeneca’s Imfinzi showed encouraging results in NSCLC

MorphoSys and Incyte’s Monjuvi® (Tafasitamab-cxix) showed encouraging results in DLBCL

Genentech’s Tecentriq in combination with Avastin reduced the risk of cancer recurrence in HCC patients

Merck’s Keytruda in combination with chemo significantly improved survival in Biliary Tract Cancer